| Expression pattern: |
UP |
| Associated gene: |
MET, Exportin-1 |
| Associated microRNA: |
- |
| Biological function: |
Biomarker to identify/stratify and longitudinally monitor patients with high MET activity and MET amplification (including acquired resistance) and to track therapy response/clonal evolution. |
| Molecular mechanism: |
circMET abundance correlates with MET expression/activity and MET gene amplification; cytoplasmic enrichment depends on Exportin-1. |
| Biological pathway or process: |
other pathway/process (other); drug resistance (promotes) |
| Detected method: |
Q
B
|
| Validation methods: |
Bioinformatics Analysis; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Northern Blot; Actinomycin D / DRB Stability Assay; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; FISH / smFISH; IHC (Immunohistochemistry); In Vivo Animal Model; Transfection; CCK8; Colony Formation Assay; Digital PCR |
| Clinical significance: |
circMET measurement identifies and tracks patients with high MET activity and can non-invasively monitor emergence of MET amplification as acquired resistance and therapy response using liquid biopsy. |
| Description: |
This study identifies circMET (hsa_circ_0082002), a MET exon 2-derived circRNA, and shows it is increased in high-MET tumors. circMET levels correlate with MET expression/activity and MET amplification, enabling non-invasive patient stratification and longitudinal monitoring of MET-driven acquired resistance and response to anti-MET therapies via plasma cfRNA. |
| Confidence score: |
0.8124 |